Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

Failed longevity drugs within the ITP | Peter Attia & Rich Miller — Whalespan

Content›Video›Failed longevity drugs withi…

Failed longevity drugs within the ITP | Peter Attia & Rich Miller

Peter Attia11m · 2024-01-03

Claims Made

22

Claims Supported

4

Support Rate

18%

Support rate

4 of 22 claims supported

4 supported18 partial / not

Claims from this content

19

✕Not SupportedA famous study on resveratrol in mice used a diet poisoned with 60% coconut oil, causing liver swelling and respiratory failure, which is not a valid model for aging.✕Not SupportedThe claim that resveratrol activates sirtuins has been questioned by biochemists, and original data on worms showing its efficacy has been disconfirmed by multiple labs.✕Not SupportedResveratrol was heavily hyped as a longevity agent but evidence suggests it does not extend lifespan in mice and its proposed mechanisms of action are questionable.◐Partially SupportedMetformin was not successful in isolation in the ITP mouse study, but was successful when combined with rapamycin.

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

✓Well Supported

Using aging rate indicators for pre-screening could increase the hit rate of lifespan-extending drugs from ~10-15% to 50%.

✕Not SupportedNAD precursors like NR and NMN increase NAD levels but lack demonstrated phenotypic benefit in normal or aging individuals outside pathological states.

✕Not SupportedThe Intervention Testing Program (ITP) tested resveratrol using concentrations suggested by David Sinclair, and it did not extend lifespan in regular mice.

◐Partially SupportedThe amount of resveratrol in red wine is insufficient to achieve potential health benefits.

✕Not SupportedThe evidence for resveratrol's health benefits is largely unconvincing due to biased studies and questionable findings.

◐Partially SupportedNMN is a metabolite of NR with potentially better bioavailability and profiles, and warrants testing if affordable and feasible.

◐Partially SupportedThe theoretical case for metformin being beneficial for health is plausible, though not completely proven.

◐Partially SupportedFailure of a drug in mouse lifespan studies does not preclude efficacy in humans.

✓Well SupportedInterventions aiming to rescue age-associated changes in NAD levels are plausible.

◐Partially SupportedThere is more faith in the possibility that NR and Metformin could still be viable in humans, even if initial mouse lifespan studies were negative.

◐Partially SupportedFinding a dose of NAD+ modulating drugs that benefits critical cells without harming others may be challenging but could be effective.

◐Partially SupportedFuture testing of nicotinamide riboside (NR) may involve combination with other drugs or enzyme inhibitors.

◐Partially SupportedApproximately 20-25 applications for drug testing are received annually, with 8-10 having a plausible case for testing, and a current hit rate of about 10% for significant lifespan benefits.

✕Not SupportedThe dosage of resveratrol suggested by experts for Alzheimer's patients varied over a million-fold, indicating a lack of consensus.

◐Partially SupportedThere is a reasonable chance of significant findings regarding NMN and the nicotinamide modulating family.